Compare Ascendis Pharma A/S (ASND) vs Manchester United PLC (MANU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Manchester United PLC — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Manchester United PLC trades at $22.28 (market cap $3.80B). The key difference: Ascendis Pharma A/S is far larger — about 4.7× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MANU | |
|---|---|---|
Market Cap | $17.74B | $3.80B |
Sector | Health | Media |
52-Week High | $277.18 | $23.53 |
52-Week Low | $163.32 | $15.10 |
Enterprise Value | $18.11B | $4.72B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Manchester United (MANU) trades at $22.04, up 0.18% today, with a bullish technical signal and positive news flow around stadium development. The company reported mixed quarterly earnings but achieved Champions League qualification, boosting future revenue prospects. However, fundamentals show persistent net losses and negative ROE, with a high P/B ratio of 16.05 indicating premium valuation despite profitability challenges.
The outlook is cautiously optimistic, driven by stadium expansion plans and improved sporting performance, but significant execution risks and ongoing financial losses warrant careful monitoring. Analyst sentiment is mixed with 40% buy ratings, reflecting the balance between growth potential and current weak profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
